Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Martínez Canales, Sandra ^a   Cifuentes, Francisco ^a   De Rodas Gregorio, Miguel Lopez ^a   Serrano Oviedo, Leticia ^a   Galan Moya, Eva María ^b   Amir, Eitan ^c   Pandiella, Atanasio ^d   Gyorffy, Balazs ^e,f   Ocaña, Alberto ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b University of Castilla La Mancha   (Spain)

^c UNIVERSITY OF TORONTO   (Canada)

^d CSIC   (Spain)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYROPHILIN; HLA C ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; TOLL LIKE RECEPTOR 6; TRANSCRIPTOME;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST TISSUE; BTN2A2 GENE; CANCER RISK; CD300A GENE; CD6 GENE; CLINICAL OUTCOME; COMPARATIVE STUDY; CSF2RA GENE; DAPP1 GENE; FUNCTIONAL GENOMICS; GENE; GENE CONTROL; GENE EXPRESSION; HLA C GENE; HLA F GENE; HLA G GENE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOLOGY; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; STRUCTURAL BIOINFORMATICS; TIGIT GENE; TLR6 GENE; TRANSCRIPTOMICS; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BREAST TUMOR; FEMALE; GENETICS; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS; TRANSCRIPTOME; TREATMENT OUTCOME; UP-REGULATION;

EID: 85018337323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175128     Document Type: Article

References (17)

1. Ocana A, Pandiella A. Identifying breast cancer druggable oncogenic alterations: leasons learned and future options. Clin Cancer Res (2008); 14:961-70. https://doi.org/10.1158/1078-0432.CCR-07-1630 PMID: 18281527
2. https://www.nccn.org/professionals/physiciangls/fguidelines.asp#breast.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000); 100:57-70. PMID: 10647931
4. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014); 32:2959-66. https://doi.org/10.1200/JCO.2013.55.0491 PMID: 25071121
5. Ocana A, Diez-Gonzalez L, Adrover E, Fernandez-Aramburo A, Pandiella A, Amir E. Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time? Journal of Clinical Oncology (2015); 33:1298-1299. https://doi.org/10.1200/JCO.2014.59.7286 PMID: 25753437
6. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015); 33:23-35. https://doi.org/10.1016/j.coi.2015.01.006 PMID: 25621841
7. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni Ll. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016); 13:674-690. https://doi.org/10.1038/nrclinonc.2016.66 PMID: 27184417
8. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016); 16:599-611. https://doi.org/10.1038/nri.2016.80 PMID: 27526640
9. Blake SJ, Dougall WC, Miles JJ et al. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res (2016); 13:674-690.
10. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006); 9:121-132. https://doi.org/10.1016/j.ccr.2006.01.013 PMID: 16473279
11. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2010); 123:725-731. https://doi.org/10.1007/s10549-009-0674-9 PMID: 20020197
12. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012); 486:346-352. https://doi.org/10.1038/nature10983 PMID: 22522925
13. Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat (2014); 143:403-409. https://doi.org/10.1007/s10549-013-2763-z PMID: 24337596
14. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest (2015); 125:2046-2058. https://doi.org/10.1172/JCI80445 PMID: 25866972
15. Mihaly Z, Gyorffy B. Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis. Microarrays (Basel) (2013); 2:228-242.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013); 6: p11. https://doi.org/10.1126/scisignal.2004088 PMID: 23550210
17. Ocana A, Pandiella A. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. (2017) Oncotarget